Hoth Therapeutics Commences Next Phase of VNLG-152 Study
Solubility and formulation had been established for the drug in the treatment of dermatological diseases
NEW YORK, April 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, at Weill Cornell Medicine.
Hoth continues to examine the efficacy of RAMBAs in blocking acne pathogenic gene expression and carcinogenesis in mice. Solubility and formulation had been established for the drug for use in both human keratinocytes and mouse studies. A human keratinocyte in vitro acne study has been optimized, which uses molecules released by Propionibacterium acnes, or P. acnes, to induce an inflammatory response in these cells.
As part of the next phase of this study, the assay will be tested to explore whether VNLG-152 is capable of blocking this inflammatory response. Immediately after identifying an effective dose of VNLG-152, the researchers will conduct studies on mouse skin to determine if this drug is effective in blocking acne-like inflammation in vivo.
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Our management team is honored to collaborate with Weill Cornell Medicine as their researchers continue to explore the treatment benefits of our proprietary dermatological solution. We believe that VNLG-152 has the potential to offer a unique therapeutic benefit to people suffering from acne and psoriasis."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
To learn more, please visit www.hoththerapeutics.com.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the preclinical development of VNLG-152 and the potential development of products related to VNLG-152 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
Contacts
Investor Relations Contact:
Phone: (646) 756-2997
Email: [email protected]
www.hoththerapeutics.com
KCSA Strategic Communications
Valter Pinto, Managing Director
(212) 896-1254
[email protected]
SOURCE Hoth Therapeutics, Inc.
Share this article